Skip to Main content Skip to Navigation
Journal articles

Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.

Abstract : Sorafenib is a molecular-targeted therapy used in palliative treatment of advanced hepatocellular carcinoma (HCC) in Child-Pugh A patients. We describe the case of a patient who presented with a large HCC in the left liver associated with portal vein thrombosis (PVT). After 9 months of sorafenib treatment, reassessment showed that the tumors had decreased in size with recanalization of the portal vein. A lateral left hepatectomy was performed and pathology showed complete necrosis of the tumor. Sorafenib can downstage HCC in patients with cirrhosis allowing further surgical resection.
Document type :
Journal articles
Complete list of metadatas

Cited literature [17 references]  Display  Hide  Download

https://www.hal.inserm.fr/inserm-00850497
Contributor : Ed. Bmc <>
Submitted on : Tuesday, August 6, 2013 - 9:09:07 PM
Last modification on : Tuesday, April 7, 2020 - 5:08:05 PM
Long-term archiving on: : Wednesday, April 5, 2017 - 7:44:34 PM

Files

Identifiers

Collections

Citation

Sabrina Kermiche-Rahali, Aude Di Fiore, Fanny Drieux, Frédéric Di Fiore, Arnaud François, et al.. Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.. World Journal of Surgical Oncology, BioMed Central, 2013, 11 (1), pp.171. ⟨10.1186/1477-7819-11-171⟩. ⟨inserm-00850497⟩

Share

Metrics

Record views

538

Files downloads

540